CompanyGraph
Emergent BioSolutions Inc.
EBS · NYSE Arca · United States
emergentbiosolutions.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $676.8M, above the global median of $520.53M
- FinancialsAltman Z-Score 1.5: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
393.68MUSDvs all stocks (USD)
Revenue (TTM)
676.80MUSDvs all stocks (USD)
Profit Margin
-1.27%Beta
2.34xvs all stocks
52-Week Change
9.94%vs all stocks
Market Capitalization
393.68MUSDvs all stocks (USD)
Enterprise Value
831.39MUSDvs all stocks (USD)
Forward P/E
2.57xPrice to Sales (TTM)
0.5863xPrice to Book (MRQ)
0.7615xEnterprise to Revenue
1.23xEnterprise to EBITDA
4.99xGross Margin
51.90%Profit Margin
-1.27%Operating Margin
6.79%Return on Assets (TTM)
3.43%Return on Equity (TTM)
-1.60%Revenue (TTM)
676.80MUSDvs all stocks (USD)
Revenue per Share (TTM)
12.80USDUpdated Jul 18, 2026Quarterly Revenue Growth
-29.70%Gross Profit (TTM)
321.40MUSDvs all stocks (USD)
EBITDA (TTM)
262.30MUSDvs all stocks (USD)
Net Income (TTM)
-8.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-90.00%Operating Cash Flow (TTM)
148.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
256.21MUSDvs all stocks (USD)
Payout Ratio
0.00%Revenue
705.20MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
326.20MUSDFY2025 · Dec 31, 2025Gross Profit
379.00MUSDFY2025 · Dec 31, 2025Operating Income
112.30MUSDvs all stocks (USD)
Pre-tax Income
82.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
30.20MUSDFY2025 · Dec 31, 2025Net Income
52.60MUSDFY2025 · Dec 31, 2025EBIT
142.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
262.30MUSDFY2025 · Dec 31, 2025Research & Development
53.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
186.10MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-37.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
59.30MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.9800USDFY2025 · Dec 31, 2025EPS (Diluted)
0.9300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
52.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
164.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
139.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
209.10MUSDFY2025 · Dec 31, 2025Income Tax Paid
40.00MUSDFY2025 · Dec 31, 2025Interest Paid
49.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
52.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
95.80MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-4.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.20MUSDFY2025 · Dec 31, 2025Other Non-cash Items
10.20MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
25.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-8.40MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-23.70MUSDFY2025 · Dec 31, 2025Capital Expenditures
24.40MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
45.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
69.40MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-108.70MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-24.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.20MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-138.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.80MSharesUpdated Jul 18, 2026Float Shares
49.38MSharesUpdated Jul 18, 2026Shares Short
10.27MSharesUpdated Jul 18, 2026Short Ratio
10.15daysvs all stocks
Short % of Shares Outstanding
20.21%vs all stocks
% Held by Insiders
3.85%vs all stocks
% Held by Institutions
87.07%vs all stocks
Total Cash (MRQ)
160.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.11USDUpdated Jul 18, 2026Total Debt (MRQ)
584.60MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.12xCurrent Ratio (MRQ)
4.29xBook Value per Share (MRQ)
10.10USDUpdated Jul 18, 2026Total Assets
1.32BUSDvs all stocks (USD)
Total Current Assets
662.50MUSDFY2025 · Dec 31, 2025Total Liabilities
796.00MUSDFY2025 · Dec 31, 2025Total Non-current Assets
656.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
663.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
132.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
205.40MUSDFY2025 · Dec 31, 2025Accounts Receivable
66.80MUSDFY2025 · Dec 31, 2025Inventory
343.40MUSDFY2025 · Dec 31, 2025Accounts Payable
55.60MUSDFY2025 · Dec 31, 2025Other Current Liabilities
15.80MUSDFY2025 · Dec 31, 2025Long-term Debt
572.10MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
53.90MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-159.80MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
522.60MUSDvs all stocks (USD)
Treasury Stock
252.60MUSDFY2025 · Dec 31, 202552-Week Low
5.62USDUpdated Jul 18, 202652-Week High
14.06USDUpdated Jul 18, 202652-Week Change
9.94%vs all stocks
Beta
2.34xvs all stocks
50-Day MA
8.35USDUpdated Jul 18, 2026200-Day MA
9.72USDUpdated Jul 18, 2026Avg 10-Day Volume
745.33KSharesUpdated Jul 18, 2026Avg 30-Day Volume
919.46KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.1900USDUpdated Jul 18, 2026Other Income / Expense
29.80MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.01
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.06Revenue Growth YoY: -0.30
Financial Health
Altman Z-Score 1.5: grey zoneSignificant
Altman Z-Score: 1.50
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $676.8M, above the global median of $520.53MNotable
Revenue (USD): 676,800,000Global Median: 520,528,949.311
Levered free cash flow is $256.21M, above the global median of $16.24MNotable
Levered free cash flow (USD): 256,212,496Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
GoldQuest Mining Corp.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Bringspring Science & Technology Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Hubei Jiuzhiyang Infrared Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown